$ACRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACELRX PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACELRX PHARMACEUTICALS INC. Get notifications about new insider transactions in ACELRX PHARMACEUTICALS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16 2013 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN STEPHEN J | Director | Option Exercise | P | 10.55 | 15,000 | 158,250 | 15,000 | |
| Sep 13 2013 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | A | 10.55 | 15,000 | 158,250 | 15,000 | |
| Jul 24 2013 | ACRX | ACELRX PHARMACEUTI ... | PERCEPTIVE ADVISORS LLC | 10% Owner | Buy | P | 11.65 | 850,000 | 9,902,500 | 5,858,400 | 5 M to 5.9 M (+16.97 %) |
| Jun 10 2013 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 8.10 | 10,000 | 81,000 | 60,000 | 50 K to 60 K (+20.00 %) |
| May 29 2013 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Buy | P | 8.39 | 50,000 | 419,500 | 75,000 | 25 K to 75 K (+200.00 %) |
| May 29 2013 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Buy | P | 7.78 | 25,000 | 194,500 | 25,000 | 0 to 25 K |
| Mar 05 2013 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Payment of Exercise | F | 4.96 | 1,363 | 6,760 | 18,139 | 19.5 K to 18.1 K (-6.99 %) |
| Mar 05 2013 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Payment of Exercise | F | 4.96 | 1,549 | 7,683 | 26,578 | 28.1 K to 26.6 K (-5.51 %) |
| Feb 07 2013 | ACRX | ACELRX PHARMACEUTI ... | KING RICHARD | Director | Option Exercise | A | 5.31 | 507,057 | 2,692,473 | 507,057 | |
| Feb 13 2013 | ACRX | ACELRX PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 5.45 | 15,000 | 81,750 | 15,000 | |
| Feb 07 2013 | ACRX | ACELRX PHARMACEUTI ... | WELCH JAMES H | Chief Financial Off ... | Option Exercise | A | 5.31 | 141,775 | 752,825 | 141,775 | |
| Feb 07 2013 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 5.31 | 388,137 | 2,061,007 | 388,137 | |
| Feb 07 2013 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 5.31 | 131,316 | 697,288 | 131,316 | |
| Feb 07 2013 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 5.31 | 124,343 | 660,261 | 124,343 | |
| Dec 11 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Buy | P | 3.31 | 52,213 | 172,825 | 139,621 | 87.4 K to 139.6 K (+59.73 %) |
| Dec 11 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Buy | P | 3.31 | 2,364,705 | 7,827,174 | 6,323,534 | 4 M to 6.3 M (+59.73 %) |
| Jul 26 2012 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Option Exercise | A | 3.11 | 12,500 | 38,875 | 12,500 | |
| Jul 26 2012 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | A | 3.11 | 12,500 | 38,875 | 12,500 | |
| Jul 26 2012 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Option Exercise | A | 3.11 | 12,500 | 38,875 | 12,500 | |
| Jul 26 2012 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Option Exercise | A | 3.11 | 12,500 | 38,875 | 12,500 | |
| Jul 26 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | A | 3.11 | 12,500 | 38,875 | 12,500 | |
| Jul 26 2012 | ACRX | ACELRX PHARMACEUTI ... | HOFFMAN STEPHEN J | Director | Option Exercise | A | 3.11 | 12,500 | 38,875 | 12,500 | |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | P | 3.40 | 4,151 | 14,113 | 4,151 | |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | P | 3.40 | 188,020 | 639,268 | 188,020 | |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | P | 3.40 | 3,268 | 11,111 | 3,268 | |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Option Exercise | P | 3.40 | 60,789 | 206,683 | 60,789 | |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Buy | P | 3.40 | 4,613 | 15,684 | 87,408 | 82.8 K to 87.4 K (+5.57 %) |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Buy | P | 3.40 | 208,911 | 710,297 | 3,958,829 | 3.7 M to 4 M (+5.57 %) |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Buy | P | 3.40 | 3,631 | 12,345 | 199,174 | 195.5 K to 199.2 K (+1.86 %) |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | WAN MARK A | Director | Buy | P | 3.40 | 67,543 | 229,646 | 3,704,712 | 3.6 M to 3.7 M (+1.86 %) |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | Director | Option Exercise | P | 3.40 | 256,228 | 871,175 | 256,228 | |
| May 31 2012 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | Director | Buy | P | 3.40 | 284,698 | 967,973 | 4,161,933 | 3.9 M to 4.2 M (+7.34 %) |
| Mar 06 2012 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Payment of Exercise | F | 2.91 | 1,511 | 4,397 | 12,006 | 13.5 K to 12 K (-11.18 %) |
| Mar 06 2012 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Payment of Exercise | F | 2.91 | 1,717 | 4,996 | 13,643 | 15.4 K to 13.6 K (-11.18 %) |
| Feb 13 2012 | ACRX | ACELRX PHARMACEUTI ... | KING RICHARD | President and CEO | Option Exercise | A | 3.39 | 262,214 | 888,905 | 262,214 | |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 3.39 | 231,911 | 786,178 | 231,911 | |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 3.39 | 51,319 | 173,971 | 51,319 | |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | WELCH JAMES H | Chief Financial Off ... | Option Exercise | A | 3.39 | 72,579 | 246,043 | 72,579 | |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.39 | 51,319 | 173,971 | 51,319 | |
| Feb 09 2012 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.39 | 51,319 | 173,971 | 51,319 | |
| Dec 02 2011 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.79 | 10,000 | 27,900 | 50,000 | 40 K to 50 K (+25.00 %) |
| Nov 16 2011 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Buy | P | 2.90 | 40,000 | 116,000 | 40,000 | 0 to 40 K |
| Sep 28 2011 | ACRX | ACELRX PHARMACEUTI ... | EDWARDS MARK G | Director | Option Exercise | A | 3.25 | 15,000 | 48,750 | 15,000 | |
| Sep 08 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Payment of Exercise | F | 3.10 | 1,539 | 4,771 | 15,360 | 16.9 K to 15.4 K (-9.11 %) |
| Sep 08 2011 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Payment of Exercise | F | 3.10 | 1,354 | 4,197 | 13,517 | 14.9 K to 13.5 K (-9.10 %) |
| Sep 07 2011 | ACRX | ACELRX PHARMACEUTI ... | WELCH JAMES H | Chief Financial Off ... | Buy | P | 3.39 | 1,000 | 3,391 | 15,000 | 14 K to 15 K (+7.14 %) |
| Sep 07 2011 | ACRX | ACELRX PHARMACEUTI ... | WELCH JAMES H | Chief Financial Off ... | Buy | P | 3.39 | 2,000 | 6,788 | 14,000 | 12 K to 14 K (+16.67 %) |
| Sep 07 2011 | ACRX | ACELRX PHARMACEUTI ... | WELCH JAMES H | Chief Financial Off ... | Buy | P | 3.32 | 7,000 | 23,238 | 12,000 | 5 K to 12 K (+140.00 %) |
| Aug 31 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Buy | P | 3.28 | 500 | 1,640 | 17,982 | 17.5 K to 18 K (+2.86 %) |
| Aug 31 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Buy | P | 3.27 | 500 | 1,634 | 300,951 | 300.5 K to 301 K (+0.17 %) |
| Aug 24 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Buy | P | 3.01 | 1,000 | 3,010 | 17,482 | 16.5 K to 17.5 K (+6.07 %) |
| Aug 24 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Buy | P | 3.01 | 1,000 | 3,010 | 300,451 | 299.5 K to 300.5 K (+0.33 %) |
| Jun 13 2011 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Buy | P | 4.61 | 8,800 | 40,568 | 326,394 | 317.6 K to 326.4 K (+2.77 %) |
| Jun 13 2011 | ACRX | ACELRX PHARMACEUTI ... | KING RICHARD | Chief Executive Off ... | Buy | P | 4.56 | 3,500 | 15,960 | 126,957 | 123.5 K to 127 K (+2.83 %) |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | KING RICHARD | President and CEO | Option Exercise | A | 3.45 | 115,208 | 397,468 | 115,208 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | KING RICHARD | President and CEO | Grant | A | 0.00 | 123,457 | 0 | 123,457 | 0 to 123.5 K |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 3.45 | 25,000 | 86,250 | 25,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Option Exercise | A | 3.45 | 75,000 | 258,750 | 75,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Palmer Pamela P | Chief Medical Offic ... | Grant | A | 0.00 | 67,594 | 0 | 317,594 | 250 K to 317.6 K (+27.04 %) |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 3.45 | 40,000 | 138,000 | 40,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Option Exercise | A | 3.45 | 12,500 | 43,125 | 12,500 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Dasu Badri N | Chief Engineering O ... | Grant | A | 0.00 | 14,871 | 0 | 14,871 | 0 to 14.9 K |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Grant | A | 0.00 | 59,145 | 0 | 358,596 | 299.5 K to 358.6 K (+19.75 %) |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | WELCH JAMES H | Chief Financial Off ... | Option Exercise | A | 3.45 | 25,000 | 86,250 | 25,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.45 | 11,000 | 37,950 | 11,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Option Exercise | A | 3.45 | 20,000 | 69,000 | 20,000 | |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Hamel Lawrence G | Chief Development O ... | Grant | A | 0.00 | 16,899 | 0 | 16,899 | 0 to 16.9 K |
| Mar 04 2011 | ACRX | ACELRX PHARMACEUTI ... | Rosen Howard B | Director | Grant | A | 0.00 | 4,394 | 0 | 4,394 | 0 to 4.4 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | C | 0.00 | 14,713 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | S | 0.00 | 54,875 | 0 | 14,713 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | X | 0.00 | 69,588 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | X | 0.00 | 69,588 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | J | 0.00 | 40,865 | 0 | 69,588 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | C | 0.00 | 810,129 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | C | 0.00 | 218,750 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Option Exercise | C | 0.00 | 500,000 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Buy | P | 5.00 | 680,000 | 3,400,000 | 2,794,907 | 2.1 M to 2.8 M (+32.15 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Buy | C | 0.00 | 14,713 | 0 | 2,114,897 | 2.1 M to 2.1 M (+0.70 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Buy | C | 0.00 | 279,097 | 0 | 2,100,194 | 1.8 M to 2.1 M (+15.33 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Buy | C | 0.00 | 810,129 | 0 | 1,821,097 | 1 M to 1.8 M (+80.13 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Buy | C | 0.00 | 328,064 | 0 | 1,010,968 | 682.9 K to 1 M (+48.04 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | ACP IV, L.P. | 10% Owner | Buy | C | 0.00 | 682,904 | 0 | 682,904 | 0 to 682.9 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | C | 0.00 | 14,713 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | S | 0.00 | 54,875 | 0 | 14,713 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | X | 0.00 | 69,588 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | X | 0.00 | 69,588 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | J | 0.00 | 40,865 | 0 | 69,588 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | C | 0.00 | 810,129 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | C | 0.00 | 218,750 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Option Exercise | C | 0.00 | 500,000 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Buy | P | 5.00 | 680,000 | 3,400,000 | 2,794,907 | 2.1 M to 2.8 M (+32.15 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Buy | C | 0.00 | 14,713 | 0 | 2,114,897 | 2.1 M to 2.1 M (+0.70 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Buy | C | 0.00 | 279,097 | 0 | 2,100,194 | 1.8 M to 2.1 M (+15.33 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Buy | C | 0.00 | 810,129 | 0 | 1,821,097 | 1 M to 1.8 M (+80.13 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Buy | C | 0.00 | 328,064 | 0 | 1,010,968 | 682.9 K to 1 M (+48.04 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | NOHRA GUY P | Director | Buy | C | 0.00 | 682,904 | 0 | 682,904 | 0 to 682.9 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 2,562 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | S | 5.00 | 9,557 | 47,785 | 2,562 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 12,119 | 0 | 12,119 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 12,119 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | J | 0.00 | 12,119 | 0 | 12,119 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 56 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | S | 5.00 | 211 | 1,055 | 56 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 267 | 0 | 267 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 267 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | J | 0.00 | 267 | 0 | 267 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 24,878 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | S | 5.00 | 92,783 | 463,915 | 24,878 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 117,661 | 0 | 117,661 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 117,661 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 549 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | S | 5.00 | 2,048 | 10,240 | 549 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 2,597 | 0 | 2,597 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | X | 0.00 | 2,597 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 857,241 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 18,928 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 321,036 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 7,088 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 440,278 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Option Exercise | C | 0.00 | 9,721 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | P | 5.00 | 1,261,927 | 6,309,635 | 3,749,918 | 2.5 M to 3.7 M (+50.72 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | P | 5.00 | 27,863 | 139,315 | 82,795 | 54.9 K to 82.8 K (+50.72 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 27,440 | 0 | 2,487,991 | 2.5 M to 2.5 M (+1.12 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 605 | 0 | 54,932 | 54.3 K to 54.9 K (+1.11 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 520,510 | 0 | 2,460,551 | 1.9 M to 2.5 M (+26.83 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 11,492 | 0 | 54,327 | 42.8 K to 54.3 K (+26.83 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 857,241 | 0 | 1,940,041 | 1.1 M to 1.9 M (+79.17 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 18,928 | 0 | 42,835 | 23.9 K to 42.8 K (+79.17 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 481,465 | 0 | 1,082,800 | 601.3 K to 1.1 M (+80.07 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 10,630 | 0 | 23,907 | 13.3 K to 23.9 K (+80.06 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 601,335 | 0 | 601,335 | 0 to 601.3 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Three Arch Management IV, L.L. ... | 10% Owner | Buy | C | 0.00 | 13,277 | 0 | 13,277 | 0 to 13.3 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Option Exercise | C | 0.00 | 10,201 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Option Exercise | C | 0.00 | 30,605 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Buy | C | 0.00 | 13,932 | 0 | 13,932 | 0 to 13.9 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | SCHRECK THOMAS A | Director | Buy | C | 0.00 | 41,800 | 0 | 41,800 | 0 to 41.8 K |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | C | 0.00 | 2,730 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | S | 5.00 | 10,184 | 50,920 | 2,730 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | X | 0.00 | 12,914 | 0 | 12,914 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | X | 0.00 | 12,914 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | J | 0.00 | 12,914 | 0 | 12,914 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | C | 0.00 | 26,511 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | S | 5.00 | 98,875 | 494,375 | 26,511 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | X | 0.00 | 125,386 | 0 | 125,386 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | X | 0.00 | 125,386 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | C | 0.00 | 915,798 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | C | 0.00 | 312,500 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Option Exercise | C | 0.00 | 500,000 | 0 | 0 | |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Buy | P | 5.00 | 1,235,943 | 6,179,715 | 3,877,235 | 2.6 M to 3.9 M (+46.79 %) |
| Feb 18 2011 | ACRX | ACELRX PHARMACEUTI ... | Skyline Venture Partners Quali ... | 10% Owner | Buy | C | 0.00 | 29,241 | 0 | 2,651,292 | 2.6 M to 2.7 M (+1.12 %) |